Apotex Ferriprox NDA Will Seek First-Line Claim; Fall Submission Planned
This article was originally published in Pharmaceutical Approvals Monthly
Apotex’ upcoming NDA for the iron-chelating agent Ferriprox will seek a first-line indication for treatment of iron overload in thalassemia patients.
You may also be interested in...
ApoPharma's transfusional iron overload treatment has been approved in Europe since 1999, but FDA sent a "complete response" letter in 2009.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class